Thursday, February 20, 2014
Publication and contact
A cytosine methylation
signature that predicts overall survival in acute myelogenous leukemia (AML)
Studies of human samples
suggest a cytosine methylation signature can predict overall survival of
patients with AML. A nanoHELP (nano HpaII tiny fragment enrichment by
ligation-mediated PCR) assay identified genome-wide cytosine methylation
patterns in highly purified blood cells from individual patients with AML and
healthy subjects. In the samples from healthy subjects, cytosine methylation
in common myeloid progenitors was lower than that in hematopoietic stem
cells, particularly near promoters of genes involved in hematopoiesis and
leukemogenesis. In the samples from patients with AML, a signature based on
methylation at 561 loci predicted poorer overall survival. Next steps include
testing the signature in prospective clinical trials and developing a simpler
assay to determine the methylation status of loci in the signature.
Published online Feb. 20, 2014
Patent application filed;
available for licensing from the Albert Einstein College of Medicine of Yeshiva
Contact: David Silva, Albert Einstein College of Medicine of
Yeshiva University, Bronx, N.Y.
Bartholdy, B. et al. J.
Clin. Invest.; published online Feb. 3, 2014;
Contact: Ulrich Steidl, Albert Einstein College Of Medicine
of Yeshiva University, Bronx, N.Y.
Contact: Amit Verma, same affiliation as above
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]